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Background: Breast cancer is one of the most common cancer diagnoses in women. Surgical treatment is indicated in most 
patients. Postmastectomy pain syndrome (PMPS) is a debilitating neuropathic pain syndrome that develops after breast surgery. 
A review of the literature revealed no studies determining the prevalence of PMPS conducted in South Africa. The current 
anecdotal perception is that the prevalence of PMPS in the African population is low.
Objectives: The objectives of this study were to determine the prevalence of PMPS in adult female breast cancer patients 
following general anaesthesia without regional anaesthesia at the Chris Hani Baragwanath Academic Hospital (CHBAH), as well 
as the impact of various clinical and demographic variables on the prevalence of PMPS.
Methods: The research design was that of a cross-sectional descriptive study. The validated DN4 pain questionnaire was used in 
this study.
Results: The study included 92 patients. The prevalence of PMPS was found to be 38.04% (n = 35). The average duration 
that patients experienced neuropathic pain symptoms was 12.22  months (range 3–39  months). The average age of patients 
interviewed was 58.54 years (range 30–90 years). There was no statistically significant difference between age group and PMPS 
(p = 0.47). The study also showed that no statistically significant association existed between pain experienced and adjuvant 
therapy administered.
Conclusion: Even though surgical procedures are becoming less invasive, the prevalence of PMPS after treatment for breast 
cancer remains a clinically significant problem, comparable to international literature. This necessitates the development of more 
effective prevention and treatment strategies to improve patients’ quality of life.
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Introduction
Breast cancer is one of the most common cancer diagnoses in 
women and is a significant cause of mortality and morbidity 
worldwide.1 In South Africa, a crude incidence rate of 18.5/100 000 
women was recorded between the years 1993 and 1995.2 Surgical 
treatment is indicated in most patients, either to remove the primary 
tumour or for axillary staging and dissection.3 More patients are 
surviving breast cancer as a result of progress in the development of 
diagnostic and treatment strategies. Therefore, the population at risk 
for late post-surgical complications such as chronic pain can be 
expected to increase in the future.4
Postmastectomy pain syndrome (PMPS) is a distinctive, persistent 
and debilitating neuropathic pain syndrome that can develop after 
breast surgery.4 The International Association for the Study of Pain 
(IASP) has defined persistent pain after mastectomy as chronic pain 
in the anterior aspect of the thorax, axilla, and/or upper half of the 
arm beginning after mastectomy or quadrantectomy and persisting 
for more than three months after the surgery.9 PMPS can develop 
shortly after, or up to several months after surgery and can persist 
for years. The pain is often described as neuropathic in nature and is 
usually felt in the region innervated by the affected nerves.5 The 
exact mechanism is uncertain, but is thought to be the result of 
damage to nerve pathways, particularly the intercostobrachial 
nerve (lateral cutaneous branch of T2), during operative procedures 
on the breast and/or axilla.6
Chronic pain can have wide-ranging effects on health, 
functioning and quality of life. Studies4,7,13 conducted previously 
show a significant number of postmastectomy breast cancer 
survivors (ranging from 20% to 40% in these studies4,7,13) 
experience chronic pain that interferes with physical functioning, 
work, mood, sleep, relationships and enjoyment of life. 
Furthermore, chronic pain syndromes are often underestimated 
and poorly managed by healthcare providers.7
A review of the literature revealed no studies determining the 
prevalence of PMPS conducted in South Africa, specifically at the 
Chris Hani Baragwanath Academic Hospital (CHBAH), a tertiary 
referral hospital in Johannesburg. The majority of breast surgery 
at CHBAH is performed using general anaesthesia with 
intravenous analgesia. The current anecdotal perception is that 
the prevalence of PMPS at the CHBAH breast surgery follow-up 
clinic is low, contrary to international studies.
The aim of this study was to determine the prevalence of PMPS in 
adult female breast cancer patients following general anaesthesia 
without regional anaesthesia at the CHBAH surgical follow-up 
breast clinic, as well as the impact of various clinical and 
demographic variables (e.g. age, adjuvant therapy) on the 
prevalence of PMPS.
Research methodology
The research design was a cross-sectional descriptive study 
assessing chronic pain in breast cancer survivors. A convenience 
sample of women who had undergone mastectomy for breast 
cancer at the CHBAH were recruited and interviewed, using 
consecutive sampling, when returning to the breast surgery 
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clinic for routine follow-up examinations. Approval to conduct 
this study was obtained from the Postgraduate Committee and 
the Human Ethics Committee of the University of the 
Witwatersrand (M110705). Informed written consent was 
obtained from all the participants enrolled in this study. This 
study did not involve any drug or therapeutic management, and 
was conducted by adhering to good clinical research practice 
and the Declaration of Helsinki.11
According to international studies, the estimated average 
prevalence of PMPS is 35%. This prevalence estimation was used, 
along with a 10% precision level (power 90%) and 95% 
confidence interval (CI) in consultation with a biostatistician, to 
statistically calculate the sample size using STATCALC, a statistical 
programme under Epi Info™ (version 6) (CDC, Atlanta, GA, USA). 
A total sample size of 100 patients was used in this study.
The inclusion criteria were: female adult patients 18  years and 
older who had radical or modified radical mastectomy, as well as 
breast-conserving surgery with axillary lymph node dissection 
(ALND), for breast cancer under general anaesthesia with 
intravenous analgesia and no regional anaesthesia; at least three 
months post-surgery; attending routine follow-up at the breast 
clinic; no recurrence of breast cancer; patients who may have 
received adjuvant therapy pre- or post-surgery and able to 
communicate effectively with or without a translator.
Exclusion criteria included: conservative (without ALND), 
reconstructive or corrective breast surgery; regional anaesthesia 
as part of the anaesthetic management; chronic pain caused by 
anything other than PMPS, for example, cancer relapse, new 
breast cancer, other metastatic disease, post-surgical wound 
infection, lymphoedema and patients whose medical records 
were incomplete.
The prevalence of chronic pain after mastectomy was assessed 
using the definition of PMPS, which is based on three criteria: 
timing of the pain, character of the pain, and pain location. The 
pain should persist, either continuously or intermittently, beyond 
the normal healing time of three months. It should be typical of 
neuropathic pain, described in terms of numbness, pins and 
needles, burning, tingling etc. The pain should be located in the 
axilla, arm, shoulder, or chest wall on the side of surgery.5 The 
participants were asked the following initial question: ‘Have you 
experienced pain in the region of the operation lasting more 
than three months?’ The study questionnaire was then 
administered to those individuals who answered in the 
affirmative during the interview, in order to differentiate 
nociceptive from neuropathic (PMPS) pain.
The study questionnaire used for the purposes of this study was 
the DN4 Questionnaire (Didier Bouhassira, Paris, France). Key 
factors that contributed to the use of the DN4 Questionnaire in 
this study include the following: the integration of self-reported 
symptoms and physical examination, leading to enhanced 
precision rather than self-report alone; high discriminatory value 
for the identification of neuropathic pain; brevity and ease of 
scoring. The DN4 Questionnaire consists of a total of 10 items 
that are grouped in four sections. A score of 1 is given to each 
positive item and a score of 0 is given to each negative item. The 
cut-off value for the diagnosis of neuropathic pain is a total score 
of 4 out of 10.15 When examining the participants: light touch 
sensation was assessed using a tissue; pinprick sensation was 
assessed using a 25-gauge needle, and tactile allodynia was 
assessed by movement of a tissue over the painful area. Presence 
or absence of hypoalgesia, hyperalgesia and allodynia was 
noted.
Various demographic and clinical variables were also obtained 
by examining the patients’ medical records and reviewing the 
patient database at the breast clinic. These included age, date of 
surgery, whether the patient received any adjuvant therapy 
(chemotherapy and/or radiotherapy), and which analgesic 
medications were prescribed. Furthermore, the anaesthetic 
record was reviewed to ensure that the procedure was performed 
with general anaesthesia and intravenous analgesia alone, and 
that no regional block or local anaesthetic infiltration of the 
surgical site was performed.
Raw data were captured and analysed using the software 
program STATA/IC™ (version 12) (StataCorp LP, College Station, 
TX, USA), with the assistance of a biostatistician. The findings 
were described and analysed using descriptive and inferential 
statistics. Student’s t-test for continuous variables and the chi-
square test for categorical variables were used where appropriate. 
P-values of  <  0.05 were considered statistically significant, and 
95% confidence intervals were calculated, where indicated. 
Individuals with missing information from the questionnaire 
were excluded from the analysis.
The reliability and validity of this study was ensured by the 
following: use of a standardised patient interview process 
conducted by one researcher; use of the DN4 Questionnaire, 
which has been validated and standardised in several languages 
with a high sensitivity (83%) and specificity (90%) in 
discriminating neuropathic pain; and stringent application of 
recruitment strategies and the inclusion and exclusion criteria to 
avoid the same patients being enrolled more than once.
Study results
During the seven-month data-collection period (September 
2011 to March 2012), 100 African patients were interviewed at 
the CHBAH breast surgery follow-up clinic. Four patients were 
excluded due to incomplete data capture and one patient was 
mistakenly interviewed twice. A further three patients reported 
non-neuropathic chronic postoperative pain (DN4 pain-score 
less than 4), therefore the data analysis included 92 patients. 
Figure 1 illustrates the data-collection procedure.
There was a wide variability in the duration of time since surgery 
(range 3–96 months) within the total sample interviewed. Of the 
92 patients, 66 (71.74%) were between 3 and 20 months post-
surgery, 22 patients (23.91%) were between 21 and 40 months 
post-surgery, and 4 patients (4.35%) were between 41 and 
96 months post-surgery.
Of the 92 patients included in the data analysis, 35 fulfilled the 
criteria for chronic PMPS. These criteria excluded non-
neuropathic pain, pain outside the distribution of the nerves 
affected, pain directly related to the surgery or wound-healing 
process, and a DN4 pain score of < 4. In addition, these patients 
received general anaesthesia with intravenous analgesia and no 
regional block. The prevalence of PMPS in this study was 38.04%.
The median DN4 pain score among the 35 patients interviewed 
within the PMPS group was 6 (ranging from 4 to 8). The majority 
of patients (60%) with PMPS scored between 6 and 7 on the DN4 
Questionnaire (Table 1).
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The average duration that patients with PMPS (n = 35) had 
experienced neuropathic pain symptoms at the time of this 
study was 12.22  months (range 3–39  months). The majority of 
these patients (21 out of 35; 60%) had experienced neuropathic 
pain symptoms for between 3 and 10 months at the time of this 
study.
The mean age of patients interviewed (n = 92) was 58.54 years, 
ranging from 30 to 90 years (SD 14.22). Table 2 shows the age-
group distribution of patients with PMPS. The majority of patients 
with PMPS (n = 20, 57.14%) were in the 41– to 60-year age group. 
Further analysis of the data was carried out to test for the 
association between pain experienced and the age of patients. 
Patients with pain were slightly younger at 57.17 years (n = 35; 
SD 14.42) than those without pain at 59.38  years (n = 57; SD 
14.16). The mean difference between the ages of the two groups 
was 2.21 years with a 95% CI of –3.87 to 8.30. Statistically there 
was no significant relationship between age and PMPS (t = 0.72; 
degrees of freedom = 90; p = 0.47).
Table 3 indicates that 52 of the 92 patients interviewed (56.52%) 
received adjuvant cancer therapy as part of their treatment 
Figure 1: Flow diagram of data-collection procedure.
Table 1: DN4 pain scores within the PMPS group
DN4 pain score (/10) Frequency % Cumulative
4 6 6.52 6.52
5 5 5.43 11.95
6 11 11.96 23.91
7 10 10.87 34.78
8 3 3.26 38.04
Total 35 38.04
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occurrence. This may be due to the occurrence of PMPS in the 
context of a potentially life-threatening condition where it is 
perceived as relatively less important. Also, medical professionals 
may not specifically ask about PMPS or disregard the symptoms 
as innocent.5
In this study, patients with PMPS experienced neuropathic pain 
symptoms for between 3 and 39 months (average 12.22 months). 
The majority of these patients (60%) experienced symptoms for 
between 3 and 10 months post-treatment at the time of this study. 
Additionally, there was a wide variability in the duration of time 
since surgery within the total sample interviewed. This ranged 
from 3 to 96  months. The majority of patients (71.74%) were 
between 3 and 20  months post-surgery. Similarly, in the 
international literature, the mean time from surgery to 
questionnaire varied from 18 months to 9 years with the prevalence 
of PMPS ranging from 24% to 52% in these studies.6,8,12,13 There is 
some evidence that the prevalence of chronic pain and its 
intensity diminish over time. This may be due to women 
developing adaptation mechanisms to learn to cope with their 
chronic pain.4
The mean age of patients interviewed in this study (58.54 years) 
was comparable with the mean age of study populations in 
other studies.5,13 Of interest is the finding that the majority of 
patients with PMPS (n = 20, 57.14%) were middle-aged (41- to 
60-year age group) compared with 34.29% (n = 12) in older 
patients (61- to 90-year age group), and 8.57% (n = 3) in young 
patients (20- to 40-year age group). However, this study failed to 
show any statistically significant relationship between age and 
PMPS (p = 0.47). Several other studies have identified younger 
age as a significant risk factor for PMPS.5,6,8,12 It has been suggested 
that younger, pre-menopausal patients have more aggressive 
disease requiring more invasive surgery and adjuvant therapy. 
Younger women can also be more anxious and have a lower 
threshold to unusual sensations.5 However, Carpenter et al.13 did 
not find any association between age and pain after breast 
surgery.
Adjuvant cancer therapy has been found to be associated with 
PMPS in various studies. Gartner et al.8 found that radiation 
therapy was an independent and significant risk factor for 
reporting pain, but without relation to the extension of the 
radiation field on pain severity. Their study also showed that the 
use of chemotherapy had no independent association with pain. 
regime. Of the 52 patients, 3 (3.26%) received radiotherapy, 19 
patients (20.65%) received chemotherapy, and 30 patients 
(32.61%) received combination chemo-radiation therapy. 
Further analysis of the data was carried out to test for associations 
between pain experienced and adjuvant cancer therapy 
administered. No statistically significant associations existed 
between pain experienced and chemotherapy administered (p = 
0.31; 0.05% level of significance), radiation therapy administered 
(p = 0.84; 0.05% level of significance) and combination chemo-
radiation therapy administered (p = 0.79; 0.05% level of 
significance).
The probability of having pain following adjuvant cancer therapy 
was 42.31% (22 patients of 52). The probability of having no pain 
following adjuvant cancer therapy was 57.69% (30 patients of 
52). The odds of having pain if adjuvant cancer therapy was 
received were calculated as 0.73. Similarly, the odds of having 
pain if no adjuvant cancer therapy was received were calculated 
as 0.48. The odds ratio of the ‘no adjuvant therapy group’ versus 
the ‘adjuvant therapy group’ was calculated as 1.52 (0.73/0.48). 
This meant that experiencing pain was 1.52 times more likely to 
occur in patients who received adjuvant cancer therapy as part 
of their treatment, compared with no adjuvant therapy, however, 
the 95% confidence interval was wide (95% CI 0.64–3.60, p > 
0.05, z-score 1.96).
The majority of patients interviewed at the CHBAH breast surgery 
follow-up clinic were prescribed simple and combination 
analgesic medications for their chronic pain. These included: 
paracetamol, paracetamol/codeine combination, and non-
steroidal anti-inflammatory drugs (e.g. ibuprofen, naproxen, 
indomethacin).
Discussion
The prevalence of PMPS among African patients in this study was 
found to be 38.04%. This is similar to results obtained in other 
studies.5, 6, 8, 12–14 Estimates of the prevalence of PMPS vary widely 
in the literature. This may be due to differing measurements of 
pain and its consequences, differing definitions of persistent 
pain, varying combinations of surgery and adjuvant therapy, and 
variations in time since surgery.4
It is essential to consider why the prevalence of PMPS is still 
regarded as being relatively infrequent, even though several 
studies, including this study, have shown that PMPS is a common 
Table 2: Age distribution of patients with PMPS
Age group Frequency % Cumulative
< 41 (young) 3 8.57 8.57
41–60 (middle-aged) 20 57.14 65.71
> 60 (older) 12 34.29 100.00
Total 35 100.00
Table 3: Adjuvant therapy administered to patients with and without PMPS
No adjuvant therapy, 
no. (%)
Chemotherapy, no. 
(%)
Radiation therapy, 
no. (%)
Combination chemo-
radiation therapy, 
no. (%)
Total
No PMPS 27 (47.37%) 10 (17.54%) 2 (3.51%) 18 (31.58%) 57
PMPS 13 (37.14%) 9 (25.71%) 1 (2.90%) 12 (34.29%) 35
Total 40 19 3 30 92
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Additionally, the type, dose and duration of adjuvant therapy 
(chemotherapy, radiation therapy or combination chemo-
radiation therapy) administered to patients was beyond the 
scope of this study.
Another potential bias that could have been reflected in the 
results was the possibility that patients experiencing PMPS for a 
prolonged period of time could have adapted their response to 
the chronic pain that they were experiencing. This could have 
resulted in over-reporting or under-reporting of pain symptoms.
In conclusion, PMPS is a frequent and important problem that is 
often underestimated in the African population. It has the 
potential to affect various aspects of patients’ lives and poses a 
considerable economic and healthcare burden. The development 
of more effective identification, prevention and treatment 
strategies is therefore recommended at the CHBAH. A multi-
modal approach is most likely to influence the development of 
PMPS. This includes the use of an appropriate diagnostic/
screening tool for accurate identification of neuropathic pain 
(e.g. DN4 Questionnaire), nerve-sparing surgery, medical 
analgesic therapies (e.g. pregabalin, gabapentin, tricyclic 
antidepressants, serotonin norepinephrine reuptake inhibitors, 
opioids), and non-pharmacological therapies (e.g. psychotherapy, 
physiotherapy, transcutaneous electrical nerve stimulation).
Perioperative anaesthetic techniques for the relief of severe 
acute pain may also play a role in reducing the prevalence of 
PMPS. Preventative regional anaesthesia (e.g. epidural analgesia, 
paravertebral block) commenced before the surgical incision 
and continued into the postoperative period reduces the 
incidence of chronic postsurgical pain.10,17 Additionally, regional 
analgesia may decrease the risk of recurrence or metastases after 
surgery for breast cancer.17 It is therefore recommended that 
these anaesthetic techniques be implemented on a regular basis 
at the CHBAH.
Referral to an appropriate pain clinic is an important consideration 
for suitable evaluation and management of these patients. This 
will involve discussion with, and education of, nursing staff, 
medical colleagues and patients, in both inpatient and outpatient 
settings.
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